The relationship between statin use and total hip BMD change was robust to adjustment of age , sex , race and smoking status ( P = 0.02 ) and strengthened by inclusion of baseline ( P = 0.01 ) and week 48 change in soluble tumour necrosis factor - receptor ( sTNFR ) -1 ( P = 0.009 ) .